Novasys gets $13 million financing:
This article was originally published in Clinica
Executive Summary
Novasys has secured $13 million in a financing, which will enable it to continue developing an investigational, non-surgical treatment for female stress urinary incontinence. The Sunnyvale, California company recently completed the treatment of 41 women with the condition - it is currently collecting and analysing the clinical results. Novasys says that 80% of the 25 million sufferers of bladder control problems in the US are women. Stress urinary incontinence is the most common incontinence problem for women.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.